Welcome to our
Q3 Report 2022
Q3 Report 2022
Letter from our CEO
Guided by our purpose to bring transformational medicines to patients around the world to help them live longer and healthier lives, we are today announcing our Forward, Faster strategy to accelerate growth and value creation by reshaping the way we innovate and operate.
Dr. Paul Stoffels, CEO
We are very proud that Jyseleca, our first marketed medicine, continues to perform very well with a growing European base and a solid €60.5 million in net sales as of 30 September. As a result, we increase our 2022 net sales guidance to €80-€90 million.
Bart Filius, President, COO & CFO